Ebola Vaccine Trial Opens in Liberia

Study Led by Liberia-NIH Partnership Will Test Two Experimental Vaccines

Publish Date:

Monday, February 2, 2015

Category:

News Organization:

National Institute of Allergy and Infectious Diseases

Source URL:

A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The Partnership for Research on Ebola Vaccines in Liberia or PREVAIL, a Phase 2/3 study, is designed to enroll approximately 27,000 healthy men and women aged 18 years and older.